Roth Capital lowered its price target for the stock to $32 from $38 a share. 580% upside from current levels.
Despite good news the stock fell yesterday by a wrongly titled article by Seeking Alpha - The article was later deleted.
MarketWatch:
"DiaMedica said DM199 is demonstrating clinically meaningful improvements in kidney function in cohorts 1 and 2, as measured by simultaneously stabilizing estimated glomerular filtration rate and decreasing urine albumin-to-creatinine ratio. In participants who were hypertensive, DM199 also reduced blood pressure by clinically significant levels.
DM199 was well tolerated across all cohorts, with no DM199-related severe adverse events or discontinuations due to drug-related adverse events. Adverse events were generally mild to moderate in severity, with the most common being local injection site irritation that resolved, the company said.
The company said it will continue the trial of DM199 in IgA nephropathy and hypertensive African Americans with chronic kidney disease, and begin the pivotal Phase 2/3 study in acute ischemic stroke later this summer."
/ Just wanted to share the recent news about Diamedica. I'm bullish and long since earlier.
Submitted June 30, 2021 at 12:20AM by flissan https://ift.tt/3hmHgIz
